- Medical School - Yale University School of Medicine (1983-1987)
- Residency - New York Presbyterian Hospital, Cornell Campus (1987-1990), Internal Medicine
- Fellowship - Dartmouth-Hitchcock Medical Center (1990-1995), Hematology Oncology
- Fellowship - The University of Chicago (1996-1998), Molecular Oncology
Suzanne Conzen, M.D.
- Andrea L. Simmons Distinguished Chair in Cancer Research
- Internal Medicine - Hematology/Oncology
Suzanne D. Conzen, M.D., is a Professor in the Department of Internal Medicine and Chief of the Division of Hematology and Oncology at UT Southwestern Medical Center. She specializes in the diagnosis and treatment of breast cancer.
Dr. Conzen earned her medical degree at Yale School of Medicine and completed her residency in internal medicine at New York Hospital-Cornell Medical Center. She then received advanced training in hematology and medical oncology through a clinical fellowship at Dartmouth-Hitchcock Medical Center and in molecular oncology through a research fellowship at Dartmouth Medical School. She also holds a master’s degree from the London School of Hygiene & Tropical Medicine.
Certified by the American Board of Internal Medicine in medical oncology, she joined the UT Southwestern faculty in 2019.
An established physician-scientist with multiple National Cancer Institute grants, Dr. Conzen focuses her lab’s research on the role of the glucocorticoid receptor in prostate, breast, and ovarian cancers. Her previous research at the University of Chicago led to the recognition of a role for glucocorticoid receptor signaling in breast cancer biology and, more recently, in cancer progression and therapy-resistance in prostate and ovarian cancer. Dr. Conzen also receives peer-reviewed funding from the Breast Cancer Research Foundation. She has published countless academic articles, contributed chapters to several books, and delivered scores of presentations.
Dr. Conzen is a member of the TBCRG endocrine resistance working group, and she previously served on the CALGB/Alliance breast committee. In addition, she has served as senior editor of Cancer Research and as Chair of the National Institutes of Health’s Cancer Etiology Study Section.
In 2006, she was elected to the American Society for Clinical Investigation.
Correlation of In Vivo and Ex Vivo ADC and T2 of In Situ and Invasive Murine Mammary Cancers.
Fan X, Macleod K, Mustafi D, Conzen SD, Markiewicz E, Zamora M, Vosicky J, Mueller J, Karczmar GS, PloS one 2015 10 7 e0129212
Glucocorticoid receptor ChIP-sequencing of subcutaneous fat reveals modulation of inflammatory pathways.
Singh P, Brock CO, Volden PA, Hernandez K, Skor M, Kocherginsky M, Park JE, Brady MJ, Conzen SD, Obesity (Silver Spring, Md.) 2015 Nov 23 11 2286-93
Mammary Adipose Tissue-Derived Lysophospholipids Promote Estrogen Receptor-Negative Mammary Epithelial Cell Proliferation.
Volden PA, Skor MN, Johnson MB, Singh P, Patel FN, McClintock MK, Brady MJ, Conzen SD, Cancer prevention research (Philadelphia, Pa.) 2016 05 9 5 367-78
GR and ER Coactivation Alters the Expression of Differentiation Genes and Associates with Improved ER+ Breast Cancer Outcome.
West DC, Pan D, Tonsing-Carter EY, Hernandez KM, Pierce CF, Styke SC, Bowie KR, Garcia TI, Kocherginsky M, Conzen SD, Molecular cancer research : MCR 2016 08 14 8 707-19
Advanced assessment of migration and invasion of cancer cells in response to mifepristone therapy using double fluorescence cytochemical labeling.
Ritch SJ, Brandhagen BN, Goyeneche AA, Telleria CM, BMC cancer 2019 Apr 19 1 376
Non-canonical dimerization of the androgen receptor and other nuclear receptors: implications for human disease.
Jiménez-Panizo A, Pérez P, Rojas AM, Fuentes-Prior P, Estébanez-Perpiñá E, Endocrine-related cancer 2019 08 26 8 R479-R497
MRI accurately identifies early murine mammary cancers and reliably differentiates between in situ and invasive cancer: correlation of MRI with histology.
Mustafi D, Zamora M, Fan X, Markiewicz E, Mueller J, Conzen SD, Karczmar GS, NMR in biomedicine 2015 Sep 28 9 1078-86
Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set.
Li H, Zhu Y, Burnside ES, Huang E, Drukker K, Hoadley KA, Fan C, Conzen SD, Zuley M, Net JM, Sutton E, Whitman GJ, Morris E, Perou CM, Ji Y, Giger ML, NPJ breast cancer 2016 2
Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
Agyeman AS, Jun WJ, Proia DA, Kim CR, Skor MN, Kocherginsky M, Conzen SD, Hormones & cancer 2016 Apr 7 2 114-26
MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.
Li H, Zhu Y, Burnside ES, Drukker K, Hoadley KA, Fan C, Conzen SD, Whitman GJ, Sutton EJ, Net JM, Ganott M, Huang E, Morris EA, Perou CM, Ji Y, Giger ML, Radiology 2016 Nov 281 2 382-391
MRI ductography of contrast agent distribution and leakage in normal mouse mammary ducts and ducts with in situ cancer.
Markiewicz E, Fan X, Mustafi D, Zamora M, Conzen SD, Karczmar GS, Magnetic resonance imaging 2017 07 40 48-52
High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer.
Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GF, Gynecologic oncology 2017 07 146 1 153-160
Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.
Kach J, Long TM, Selman P, Tonsing-Carter EY, Bacalao MA, Lastra RR, de Wet L, Comiskey S, Gillard M, VanOpstall C, West DC, Chan WC, Griend DV, Conzen SD, Szmulewitz RZ, Molecular cancer therapeutics 2017 08 16 8 1680-1692
MRI reveals increased tumorigenesis following high fat feeding in a mouse model of triple-negative breast cancer.
Mustafi D, Fernandez S, Markiewicz E, Fan X, Zamora M, Mueller J, Brady MJ, Conzen SD, Karczmar GS, NMR in biomedicine 2017 Oct 30 10
Magnetic resonance spectroscopy detects differential lipid composition in mammary glands on low fat, high animal fat versus high fructose diets.
He D, Mustafi D, Fan X, Fernandez S, Markiewicz E, Zamora M, Mueller J, Sachleben JR, Brady MJ, Conzen SD, Karczmar GS, PloS one 2018 13 1 e0190929
Psychosocial Stress Exposure Disrupts Mammary Gland Development.
Johnson MB, Hoffmann JN, You HM, Lastra RR, Fernandez S, Strober JW, Allaw AB, Brady MJ, Conzen SD, McClintock MK, Journal of mammary gland biology and neoplasia 2018 06 23 1-2 59-73
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
West DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, Hosfield DJ, Lastra RR, Sinnwell JP, Thompson KJ, Bowie KR, Harkless RV, Skor MN, Pierce CF, Styke SC, Kim CR, de Wet L, Greene GL, Boughey JC, Goetz MP, Kalari KR, Wang L, Fleming GF, Györffy B, Conzen SD, Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Jul 24 14 3433-3446
Magnetic Resonance Angiography Shows Increased Arterial Blood Supply Associated with Murine Mammary Cancer.
Mustafi D, Leinroth A, Fan X, Markiewicz E, Zamora M, Mueller J, Conzen SD, Karczmar GS, International journal of biomedical imaging 2019 2019 5987425
Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.
Tonsing-Carter E, Hernandez KM, Kim CR, Harkless RV, Oh A, Bowie KR, West-Szymanski DC, Betancourt-Ponce MA, Green BD, Lastra RR, Fleming GF, Chandarlapaty S, Conzen SD, Breast cancer research : BCR 2019 07 21 1 82
Targeting the glucocorticoid receptor in breast and prostate cancers.
Kach J, Conzen SD, Szmulewitz RZ, Science translational medicine 2015 Sep 7 305 305ps19
- Correlation of In Vivo and Ex Vivo ADC and T2 of In Situ and Invasive Murine Mammary Cancers.
Showing 1 locations